ES2206996T3 - Metodo de formacion de imagenes para diagnostico con contraste mejorado para monitorizar terapias de intervencion. - Google Patents

Metodo de formacion de imagenes para diagnostico con contraste mejorado para monitorizar terapias de intervencion.

Info

Publication number
ES2206996T3
ES2206996T3 ES98950704T ES98950704T ES2206996T3 ES 2206996 T3 ES2206996 T3 ES 2206996T3 ES 98950704 T ES98950704 T ES 98950704T ES 98950704 T ES98950704 T ES 98950704T ES 2206996 T3 ES2206996 T3 ES 2206996T3
Authority
ES
Spain
Prior art keywords
tissue
contrast
state
interventional therapy
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950704T
Other languages
English (en)
Inventor
Randall B Lauffer
Stephen O Dunham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epix Pharmaceuticals Inc
Original Assignee
Epix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharmaceuticals Inc filed Critical Epix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2206996T3 publication Critical patent/ES2206996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

Uso de un agente de contraste para la preparación de un agente de diagnóstico para evaluar el contraste de imagen durante el curso de terapia intervencionista usando IRM mejorada con un contraste, en el que dicho agente de contraste: puede unirse a un tejido o componente de tejido diana que se somete o que se ha sometido a terapia intervencionista; tiene una afinidad específica por dicho tejido o componente de tejido; comprende un resto mejorador de imagen (IEM) y un resto de unión a tejido dependiente del estado (SDTBM), estando: el resto de unión a tejido dependiente del estado caracterizado por una capacidad de relajación R1 cuando está unido al tejido o componente de tejido en su estado desnaturalizado que es menor que aproximadamente 80% la capacidad de relajación R1 del agente de contraste cuando está unido al tejido o componente de tejido en su estado natural; y se evalúa una característica de la señal de la imagen del agente de contraste para determinar si se completa la terapia intervencionista.
ES98950704T 1997-10-02 1998-09-24 Metodo de formacion de imagenes para diagnostico con contraste mejorado para monitorizar terapias de intervencion. Expired - Lifetime ES2206996T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02

Publications (1)

Publication Number Publication Date
ES2206996T3 true ES2206996T3 (es) 2004-05-16

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98950704T Expired - Lifetime ES2206996T3 (es) 1997-10-02 1998-09-24 Metodo de formacion de imagenes para diagnostico con contraste mejorado para monitorizar terapias de intervencion.

Country Status (19)

Country Link
US (2) US6861045B1 (es)
EP (1) EP1019094B1 (es)
JP (2) JP2001518523A (es)
KR (1) KR20010030854A (es)
AT (1) ATE254479T1 (es)
AU (1) AU742438C (es)
BR (1) BR9812716A (es)
CA (1) CA2303426C (es)
DE (1) DE69819925T2 (es)
DK (1) DK1019094T3 (es)
ES (1) ES2206996T3 (es)
HU (1) HUP0101245A3 (es)
IL (1) IL134985A0 (es)
IS (1) IS2041B (es)
NO (1) NO321966B1 (es)
NZ (1) NZ503402A (es)
PT (1) PT1019094E (es)
SK (1) SK4842000A3 (es)
WO (1) WO1999017809A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6548044B1 (en) 1999-11-22 2003-04-15 Epix Medical, Inc. Imaging sexual response
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
EP1423136A4 (en) * 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
WO2005110495A1 (en) * 2004-05-18 2005-11-24 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy control in radiation therapy with proton or ion beams
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1957996A1 (en) * 2005-11-29 2008-08-20 Koninklijke Philips Electronics N.V. Distinguishing bound and unbound contrast agents using magnetic resonance
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
WO2008022263A2 (en) * 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
US9423480B2 (en) * 2008-10-27 2016-08-23 The University Of Western Ontario System and method for magnetic resonance imaging
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
US8891842B2 (en) 2010-02-02 2014-11-18 Koninklijke Philips N.V. Functional imaging
JP6148233B2 (ja) 2011-07-11 2017-06-21 インディ モレキュラー，インコーポレイテッド Ａｋｔ特異的捕捉剤、組成物ならびにその使用および製造方法
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CA2899522C (en) * 2013-04-08 2022-07-19 Sunnybrook Research Institute System and method for imaging biomarkers indicative of cardiac thermal ablation lesions
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
US10314648B2 (en) 2013-12-13 2019-06-11 The Trustees of the Universoty of Pennsylvania Coaxial ablation probe and method and system for real-time monitoring of ablation therapy
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3535278A4 (en) 2016-11-01 2020-06-24 Ohio State Innovation Foundation METHOD FOR IODING BIOMOLECULES
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US20190370956A1 (en) 2018-05-30 2019-12-05 General Electric Company Contrast imaging system and method
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
EP4143227A2 (en) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
CA2539215A1 (en) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Diagnostic imaging contrast agents with extended blood retention
TW319763B (es) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19529512C2 (de) 1995-08-10 2000-11-23 Siemens Ag Verfahren zur Phasenkontrast-MR-Angiographie und Anordnung zur Durchführung des Verfahrens
DE19543785A1 (de) 1995-11-24 1997-05-28 Philips Patentverwaltung MR-Verfahren und Anordnung zur Durchführung des Verfahrens
AU726914B2 (en) * 1996-04-01 2000-11-23 Epix Pharmaceuticals, Inc. Bioactivated diagnostic imaging contrast agents
IT1283650B1 (it) 1996-08-02 1998-04-23 Bracco Spa Chelati paramagnetici ad alta relassivita' in siero
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
AU742438C (en) * 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza

Also Published As

Publication number Publication date
NO20001707D0 (no) 2000-04-03
HUP0101245A3 (en) 2003-10-28
HUP0101245A2 (hu) 2001-08-28
NO20001707L (no) 2000-05-31
PT1019094E (pt) 2004-03-31
IS5399A (is) 2000-03-10
US6861045B1 (en) 2005-03-01
DK1019094T3 (da) 2004-02-16
WO1999017809A3 (en) 1999-05-20
US20050118103A1 (en) 2005-06-02
IL134985A0 (en) 2001-05-20
NZ503402A (en) 2002-03-01
BR9812716A (pt) 2000-08-22
KR20010030854A (ko) 2001-04-16
CA2303426A1 (en) 1999-04-15
AU742438B2 (en) 2002-01-03
DE69819925T2 (de) 2004-09-02
DE69819925D1 (de) 2003-12-24
HK1030744A1 (en) 2001-05-18
AU9668698A (en) 1999-04-27
NO321966B1 (no) 2006-07-31
CA2303426C (en) 2008-09-23
AU742438C (en) 2003-05-22
US7175829B2 (en) 2007-02-13
SK4842000A3 (en) 2000-11-07
ATE254479T1 (de) 2003-12-15
JP2001518523A (ja) 2001-10-16
IS2041B (is) 2005-09-15
JP2006077020A (ja) 2006-03-23
EP1019094A2 (en) 2000-07-19
WO1999017809A2 (en) 1999-04-15
EP1019094B1 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
ES2206996T3 (es) Metodo de formacion de imagenes para diagnostico con contraste mejorado para monitorizar terapias de intervencion.
ES2098269T3 (es) Dispositivo para tomar muestras de tejido.
BR0314789A (pt) Seringa de uso único
WO2004045377A3 (en) Method for using a fixator device
ES2170756T3 (es) Aparato y metodo para aplicar y ajustar un dispositivo de anclaje.
DK0907379T3 (da) Bioaktiveret diagnostisk billeddannelseskontrastmiddel
ATE295125T1 (de) Vorrichtung zur behandlung von hernia an bandscheiben
DK1107804T3 (da) Sprøjter og injektorer forsynet med magnetiske fluidumpåvirkningsindretninger
Sarfati et al. Impact of adjunctive testing on the diagnosis and clinical course of patients with acute appendicitis
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
JPH10248794A5 (es)
EP1997452A3 (de) Vorrichtung zur sterilen Umhüllung eines sterilisationsempfindlichen Bedienteils
EA199800881A1 (ru) Способ т1 - взвешенной магниторезонансной визуализации органов ретикуло-эндотелиальной системы
CN218922511U (zh) 内窥镜保护器
BR9808675A (pt) Dispositivo transuretral, e, bainha para um elemento de inserção transuretral
Nolan et al. The role of tissue biomechanics in the implantation and performance of inflatable penile prostheses: current state of the art and future perspective
Boddy et al. Testicular torsion
IT1275081B (it) Strumento per l'applicazione di clips metalliche per l'emostasi od altro impiego chirurgico, destinato al campo della chirurgia endoscopica o mininvasiva o simile
Lacroix et al. A model to simulate the regenerative and resorption phases of long bone fracture healing
KR101621622B1 (ko) 항문 농양 배농 수술시 초음파 이미지를 이용한 치루내관 분석시스템
Fendrych et al. The potential of and preconditions for MR tomography and MR angiography in urgent diagnosis of the source of acute intracranial subarachnoid bleeding
Lim et al. Edema of the ampulla of vater simulating carcinoma.
IT1092025B (it) Dispositivo per l'occlusione almeno temporanea di canali
KR20020009802A (ko) 신체에 들어간 후에 벌어져서 저절로 빠져나오지 않는내시경용관
IT1241616B (it) Pinza chirurgica a molteplice funzionalita'